Skip to main content

Table 1 Enrolment, interventions and assessments in the FORECAST study

From: Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST)

  Patient identification Before randomization Study treatment (5–8 days) 6–10 days post-end of treatment 30–35 days post-end of treatment
 Screening for eligibility x     
 Entry criteria   x    
 Informed consent   x    
 Venapunctiona   x    
 Urine/blood culture x    x (urine)  
 Study treatment    x   
 Electronic patient file   x   x x
 Patient questionnaire   x   x x
 Hand in study diary and  residual study medicines     x  
  1. ain case of doubt about the following exclusion criteria: pregnancy, neutropenia or renal insufficiency